Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD55 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD55 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD55 Products |
| Gene Delivery | CD55 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for CDC resistance modeling. |
View CD55 Products |
| Benchmark Ab | Anti-CD55 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View CD55 Products |
| Validator | CD55 siRNA Set For knockdown verification in functional validation assays. |
View CD55 Products |
| Related Target A | CD59 Synergistic complement regulatory protein (mCRP) that blocks MAC assembly; co-targeted to overcome CDC resistance. |
View CD59 Products |
| Related Target B | CD46 Complement membrane cofactor protein acting upstream; key partner in multi-spectral complement evasion. |
View CD46 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity (SEC-HPLC verified) and sequence-verified integrity. |
| Subfamily counter screening (CD46/CD59) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment to prevent off-target lead selection. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live CD55 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD55 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific immune-cell engagers. As first-generation therapies reach the clinic, the next wave of R&&D is targeting CD55-mediated complement decay acceleration to sensitize tumors to established monoclonal antibodies (e.g., rituximab, trastuzumab).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic institutions, Biotech startups | Solid Tumors, Autoimmune Hemolysis | Complement-Dependent Cytotoxicity (CDC) sensitization (Needs sequence-verified CD55 Lentivirus for stable cell lines) |
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biopharma | Ovarian Cancer, Colorectal Cancer | Internalization Assay (Needs high-purity, natively glycosylated CD55 ECD-Fc protein) |
| Bispecific / Multispecific | Clinical-stage Immunotherapy players | Hematological Malignancies, Refractory Solid Tumors | Simultaneous binding kinetics (Needs high-purity CD55 and CD59/CD46 cross-reactivity panels) |